Stockscreener 앱 받기
1.02
7.27%
-0.08
시간 외 거래:
1.02
전일 마감가:
$1.10
열려 있는:
$1.08
하루 거래량:
1.27M
Relative Volume:
0.73
시가총액:
$119.40M
수익:
$257.24M
순이익/손실:
$-237.89M
주가수익비율:
-0.3923
EPS:
-2.6
순현금흐름:
$-175.17M
1주 성능:
-0.97%
1개월 성능:
+30.47%
6개월 성능:
+39.53%
1년 성능:
-55.07%
1일 변동 폭
$1.01
$1.12
1주일 범위
$0.95
$1.12
52주 변동 폭
$0.6603
$2.43
Coherus Biosciences Inc Stock (CHRS) Company Profile
명칭
Coherus Biosciences Inc
전화
(650) 649-3530
주소
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
CHRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRS
Coherus Biosciences Inc
|
1.02 | 119.40M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-11-17 | 개시 | Robert W. Baird | Outperform |
| 2023-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-07-24 | 개시 | Citigroup | Buy |
| 2023-05-01 | 개시 | Truist | Buy |
| 2023-03-28 | 업그레이드 | UBS | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Neutral |
| 2022-03-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 개시 | BofA Securities | Neutral |
| 2020-04-17 | 개시 | SunTrust | Buy |
| 2019-08-13 | 개시 | Mizuho | Buy |
| 2019-08-02 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-02 | 재확인 | Maxim Group | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-07 | 개시 | H.C. Wainwright | Buy |
| 2018-08-28 | 개시 | H.C. Wainwright | Buy |
| 2018-03-09 | 재확인 | Maxim Group | Buy |
| 2017-08-08 | 재확인 | JP Morgan | Overweight |
| 2017-06-13 | 재확인 | Maxim Group | Buy |
| 2017-05-05 | 개시 | BMO Capital Markets | Outperform |
| 2016-10-19 | 개시 | Robert W. Baird | Outperform |
| 2016-09-07 | 개시 | Maxim Group | Buy |
| 2016-07-27 | 개시 | Citigroup | Buy |
| 2016-01-20 | 개시 | Credit Suisse | Outperform |
모두보기
Coherus Biosciences Inc 주식(CHRS)의 최신 뉴스
Coherus Sets Q1 2025 Earnings Date: How to Join the May 12 Conference Call - Stock Titan
Coherus BioSciences Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Coherus to Participate in Upcoming Investor Conferences | CHRS S - GuruFocus
Coherus to Participate in Upcoming Investor Conferences - GlobeNewswire
Coherus BioSciences Sets Strong Presence at Top Healthcare Conferences: Key Oncology Updates Expected - Stock Titan
Coherus Presents Promising Early Clinical Data from Phase 1 Dose - GuruFocus
Coherus BioSciences Phase 1 Trial of CHS-114 Shows Confirmed Partial Response in Cancer Patient - marketscreener.com
Coherus reports promising cancer treatment results - Investing.com
Coherus (CHRS) Advances Clinical Trial for Anti-CCR8 Antibody in Cancer Treatment | CHRS Stock News - GuruFocus
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 - The Manila Times
Coherus BioSciences Reports Promising Clinical Data for CHS-114 Combined with Toripalimab in HNSCC and Gastric Cancer - Nasdaq
Breakthrough Cancer Treatment: Coherus Drug Shows Promise in Hard-to-Treat Head and Neck Cancer Patients - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
1 of Wall Street’s Favorite Stock with Impressive Fundamentals and 2 to Turn Down - The Globe and Mail
Coherus BioSciences announces CCO Paul Reider’s resignation By Investing.com - Investing.com India
Coherus BioSciences announces CCO Paul Reider’s resignation - Investing.com Australia
3 Reasons We Love Chart (GTLS) - The Globe and Mail
Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs - Seeking Alpha
Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment - insights.citeline.com
Coherus divests Udenyca franchise to Intas for up to $558.4m - MSN
Latham & Watkins Assists Coherus BioSciences in Obtaining CFIUS Clearance - Latham & Watkins LLP
Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals
Intas acquires Neulasta biosimilar Udenyca from Coherus BioSciences - World Pharmaceutical Frontiers
Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals
Coherus BioSciences (CHRS) Completes Divestiture of UDENYCA Fran - GuruFocus
Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million - marketscreener.com
Coherus completes strategic transformation - The Pharma Letter
Accord Biopharma Announces Completion Of Udenyca(Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus Biosciences, Inc., Expanding U.S. Biosimilar Portfolio - marketscreener.com
Intas Pharmaceuticals Acquires UDENYCA Business from Coherus BioSciences - Contract Pharma
Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio - PR Newswire
Coherus Biosciences Completes UDENYCA Franchise Divestiture - TipRanks
Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio (PR Newswire) - Aktiellt
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise - GlobeNewswire
Coherus Lands Massive $558M Deal: Strategic Pivot to Oncology Extends Cash Runway to 2027 - Stock Titan
Coherus BioSciences to Repurchase $170 Million Convertible Notes - MarketScreener
Coherus BioSciences to repurchase $170 million in convertible notes - Investing.com India
Coherus BioSciences To Buy Back $170 Mln Of 1.500% Convertible Sr. Subordinated Notes - Nasdaq
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes - Bluefield Daily Telegraph
Coherus Unveils Massive $230M Debt Reduction Plan, Starting With $170M Note Buyback - Stock Titan
Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop - simplywall.st
Coherus BioSciences : Block Advisors by H&R Block to Provide Timely Support for The Home Depot’s Pro Xtra Loyalty Members - MarketScreener
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Coherus to Present Data from a Phase 1 Dose Expansion Study - GlobeNewswire
Breakthrough Cancer Treatment Data: Coherus' CCR8 Antibody Shows Promise in Head & Neck Cancer Trial - Stock Titan
Checkpoint inhibitor journey traces Chinese firms’ path to global revenue - BioWorld MedTech
Lobbying Update: $65,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Nasdaq
Shareholders Shouldn’t Be Too Comfortable With Coherus BioSciences' (NASDAQ:CHRS) Strong Earnings - simplywall.st
Statutory Earnings May Not Be The Best Way To Understand Coherus BioSciences' (NASDAQ:CHRS) True Position - Yahoo Finance
Coherus BioSciences, Inc. SEC 10-K Report - TradingView
Coherus BioSciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Coherus BioSciences Shareholders Approve UDENYCA Franchise Sale By Investing.com - Investing.com Australia
Coherus Biosciences Inc (CHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):